|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 1100 15th Street NW, Suite 400 |
Address2 | |
City | WASHINGTON |
State | DC |
Zip Code | 20005 |
Country | USA |
3. Principal place of business (if different than line 2)
City | |
State | |
Zip Code | |
Country | |
|
5. Senate ID# 3071-12
|
||||||||
|
6. House ID# 316200000
|
TYPE OF REPORT | 8. Year | 2008 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date | |
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Allison C. Wiley, Political Action Coordinator |
Date | 07/21/2008 |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
H.R. 3700/ S. 1951 Fair Medicaid Drug Payment Act of 2007
H.R. 3140 Saving Our Community Pharmacies Act of 2007
S. 3101/ H.R. 6331 Medicare Patients and Providers Act of 2008 sections on AMP, Prompt Payment of Part D Claims, DME Competitive Bidding, and Prescription Drug Pricing Updates
H.R. 6252/ S. 3144 Medicare DMEPOS Competitive Acquisition Reform Act of 2008
H.R. 5780 Medicare Clinical Practitioner Services Coverage Act of 2008
H.R. 5613 Medicaid Safety Net Act of 2008
H.R. 2408/ S. 2408 Medicare Electronic Medication and Safety Protection (E-MEDS) Act of 2007
H.R. 971 Community Pharmacy Fairness Act
S. 1827 Pharmacist Access and Recognition in Medicare (PhARM) of 2007
S. 1474 Fair and Speedy Treatment (FAST) of Medicare Prescription Drug Claims Act of 2007
H.R. 3025 Medicare Prescription Drug Savings for Our Seniors Act of 2007
S. 1954 Pharmacy Access Improvement Act (PhAIM) of 2007
(Public Law 110-28 and Public Law 110-90) Medicaid's Tamper-Resistance Prescription Pad Requirement
(Public Law 109-171) Deficit Reduction Act of 2005 section on Average Manufacturers Price (AMP)
(Docket Number: CMS -4119-F) Medicare Program; Medicare Part D Claims Data
(Docket Number: CMS 4131P) Medicare Program; Revisions to the Medicare Advantage and Prescription Drug Benefit Programs; Proposed Rule
(Docket Number: CMS-2238-IFC) Medicaid Program; Multiple Source Drug Definition
DRAFT and FINAL CMS 2009 Medicare Part D Call Letter
(Docket Number: CMS0016F and CMS0018F) Medicare Program; Standards for E-Prescribing Under Medicare Part D and Identification of Backward Compatible Version of Adopted Standard for EPrescribing and the Medicare Prescriptions Drug Program (Version 8.1); Final Rule
(Docket Numeber: CMS-2008-0009-0002)Medicare Program; Option for Prescription Drug Plans to Lower their Premiums for Low-Income Subsidy Beneficiaries
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS),
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Harry |
Hagel |
|
|
|
Kristina |
Lunner |
|
|
|
Hrant |
Jamgochain |
|
|
|
Marcie |
Bough |
|
Former Legislative Assistant in Senate |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
H. Con. Res. 342 Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest
H.R. 6353/ S. 980 Ryan Haight Online Pharmacy Consumer Protection Act of 2008
H.R. 5839 Safeguarding Americas Pharmaceuticals Act of 2008
(Public Law 110-85) Food and Drug Administration Amendment Act of 2007 (FDAAA) sections on Standardization of Prescription Drug Identifiers (Docket Number: FDA-2008-N-0120) and Technology Prescription Drug Identifiers ( Docket Number FDA-2008-N-0120) and Prescription Drug User Fee Act (PDUFA)
(Docket Number: FDA-N-0157) FDA Prescription Drug Labeling and Medication Guide
(Docket Number DEA218P) Electronic Prescriptions for Controlled Substances
(Docket Number: FDA-2008-N-0281-0001) Pilot Program To Evaluate Proposed Name Submissions; Concept Paper; Public Meeting
(Docket Number: FDA-2006-N-5015) Content and Format of Labeling for Human Prescription Drug and Biological Products; Requirements for Pregnancy and Lactation Labeling
(Docket Number: FDA-2008-N-0257-0001) Prescription Drug User Fee Act (PDUFA) IV Drug Safety Five-Year Plan
(Docket Number: FDA-2008-N-0162) Agency Information Collection Activities; Proposed Collection; Comment Request: Prescription Product Labeling: Medication Guide Requirements [related to the Paperwork Reduction Act of 1995]
DRAFT Food and Drug Globalization Act of 2008 sections on drug and medical devices
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Food & Drug Administration (FDA), Health & Human Services - Dept of (HHS), Drug Enforcement Administration (DEA),
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Harry |
Hagel |
|
|
|
Kristina |
Lunner |
|
|
|
Hrant |
Jamgochain |
|
|
|
Marcie |
Bough |
|
Former Legislative Assistant in Senate |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
H.R. 1343 Health Centers Renewal Act of 2008
H.R. 2994 National Pain Care Policy Act of 2007
H.R. 1108/ S. 265 Family Smoking Prevention and Tobacco Control Act
Under Line 17: We would like to include HHS - Office of Inspector General (OIG)
(Docket Number: HRSA-RIN-0906-AA44) Resignation of Medically Underserved Populations and Health Professional Shortage Areas
(Docket Number: OIG-126-PN) Proposed notice; Department of Health and Human Services Office of Inspector General (OIG); Draft OIG Supplemental Compliance Program Guidance for Nursing Facilities sections on pharmacies and pharmacists
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA), Health Resources & Services Administration (HRSA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Marcie |
Bough |
|
Legislative Assistant in Senate |
|
Kristina |
Lunner |
|
|
|
Hrant |
Jamgochian |
|
|
|
Harry |
Hagel |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code VET
16. Specific lobbying issues
H.R. 4053 Veterans Mental Health and Other Care Improvements Act of 2008 section on Pain Care Act
H.R. 6122 Veterans Pain Care Act of 2008
S. 2669 Veterans Medical Personnel Recruitment and Retention Act of 2008 section on Incentive Pay
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Hary |
Hagel |
|
|
|
Kristina |
Lunner |
|
|
|
Hrant |
Jamgochian |
|
|
|
Marcie |
Bough |
|
Former Legislative Assistant in Senate |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
DRAFT Fiscal 2009 Agriculture Appropriations section on FDA Funding
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Harry |
Hagel |
|
|
|
Kristina |
Lunner |
|
|
|
Hrant |
Jamgochian |
|
|
|
Marcie |
Bough |
|
Former Legislative Assistant in Senate |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address | |
||||||
City | |
State | |
Zip Code | |
Country | |
21. Client new principal place of business (if different than line 20)
City | |
State | |
Zip Code | |
Country | |
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |